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Computer screens of endless strings of four-lettered DNA
can be translated to twenty-lettered proteins, but other as yet
unknown translations will be necessary to convert this alpha-
betical soup to biology [1].
This review is addressed to clinical nephrologists with the
aim of clarifying the breakthroughs that genetics may make
in the understanding of essential hypertension. We summa-
rize some of the research performed in genetic animal
models of hypertension as well as in human hypertension,
and compare the rat with the human data in an attempt to
draw some general conclusions. A summary of the modern
genetic strategies is provided that may be used to identify
the genes responsible for essential hypertension, together
with an explanation of the genetic terminology the non-
specialist reader may find in dealing with the genetics of
complex diseases (and specifically hypertension).
Simple genetic diseases are not that simple, and
hypertension is far more complex
Though remarkable progress has been made in human
genetics, it is becoming clearer each day that even the
simplest genetic trait, that is, one caused by a monogenic
disease, exhibits a bewildering complexity [2]. Just as
examples, three prototype diseases are briefly described.
(1) Phenylketonuria, an inherited disease associated with
severe mental retardation, is caused by a defect in the gene
coding for phenylalanine hydroxylase. However, the en-
zyme deficiency is not enough to cause the disease. Expo-
sure to dietary phenylalanine is also required. In fact,
mental retardation does not occur if either factor (diet and
abnormal enzyme) is missing [3]. Thus, an interaction with
the appropriate environment is crucial for presentation of
the phenotype. (2) Over 400 mutations of the cystic fibrosis
gene have been described [4], and while some are benign
and of no clinical relevance, others cause more or less
severe forms of the disease. This means that not all the
mutations in the gene cause the disease and that different
mutations in the same gene may cause a different severity
of the disease. (3) Hereditary spastic paraplegia in its
autosomal dominant form is a clinically homogeneous,
inherited degenerative disorder of the motor system, but is
genetically heterogeneous because in different families the
disease-causing locus is attributed to different chromo-
somes, some still not identified. This suggests that there is
a common pathway on which the different abnormal gene
products must act. Any interruption of such a pathway by
any of such defective genes may cause the same phenotypic
expression of the disease [5].
More than 40 years of epidemiological studies have
identified different environmental concomitants associated
with the development of essential hypertension, and anal-
ysis of blood pressure in families has demonstrated that a
substantial proportion of blood pressure variation among
individuals is determined by genetic factors. There is no
agreement on the proportion of blood pressure variability
explained by genetic factors, but the general estimate is
around 30 to 40%. However, simple biometric calculations
by Cavalli Sforza and Bodmer demonstrated that it may be
as much as 70 to 80%, about 40% of it due to dominance
effect, which should indicate the existence of some major
gene effect over a polygenic background [6]. While much is
understood about environmental factors, the genetic fac-
tors are still largely unknown. On the other hand, genetics
(and molecular biology) permit the detection of the pri-
mary pathogenetic mechanisms of diseases by identification
of the specific DNA segment that carries the pathogenic
mutation, which should eventually allow reconstruction of
the entire sequence of events from DNA mutation to the
disease.
The classical approach in a search for the pathogenetic
mechanism of a disease is to go from the top of complexity,
at the whole organism level, down to the DNA level by
dissecting the disease phenotype into several intermediate
phenotypes at the different levels of biological organization
[7]. This top down approach (from the complexity of the
phenotype to the simple DNA sequence alteration) has
been fruitful, as it has led to the discovery of many genes
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that cause rare monogenic disorders. The situation is
considerably more complicated in the case of common,
complex diseases such as essential hypertension for several
reasons.
(1) Hypertension is caused by many genes with locus
heterogeneity or inheritance that is polygenic or oligogenic.
While there is general agreement that essential hyperten-
sion is caused by many genes, two alternatives are possible.
Different forms of essential hypertension share only the
same final phenotype but have different pathogenetic
mechanisms. In this case only any one of the many possible
mutated genes is needed to express the disease, as in the
case of monogenic forms of hypertension [8]. Alternatively,
more than one gene with at least one deleterious allele
must be simultaneously present in an individual to cause
essential hypertension. In the first case we are dealing with
locus heterogeneity, in the second with polygenic or oligo-
genic inheritance. Both alternatives may be true for essen-
tial hypertension, although it is highly likely that it is
polygenic and heterogeneous. In other words, the pheno-
type is determined by allelic variation at more than one
gene at a time. Moreover, different sets of allelic variation
of different genes may cause a similar final phenotype. To
further complicate the picture, multigenic inheritance may
be additive or epistatic.
(2) Environmental factors. The environment can alter the
sequence of events that lead from the primary DNA
mutation to the final phenotype, and act at all the different
levels of biological organization.
(3) Compensatory factors. No biological function operates
in a closed system, so any malfunctioning protein may
influence (by inducing or inhibiting) transcription of other
proteins, which in their turn may have an effect on the final
phenotype, so that the pathogenic mutation of any gene
may be obscured by the redundancy of compensatory
mechanisms and the disease phenotype may be determined
only by compensatory overexpression or inhibition of an-
other gene, whose DNA sequence is indeed normal.
Though the complexity of the picture may appear dis-
couraging due to the large number of potential candidate
genes and possible confounding interactions, among the
many physiological and/or biochemical mechanisms that
affect blood pressure only a relatively few are involved in its
long-term control [9]. Whatever the initiating event, some
alteration in kidney function must occur to produce a
permanent blood pressure increase. Guyton called this
phenomenon the “overriding role of the kidney on blood
pressure control” [9]. Recent findings on the genetics of
essential hypertension seem to support this notion. Among
the few loci or genes associated with blood pressure
regulation in humans or rats found thus far, most are
directly or indirectly involved in the renal control of sodium
balance [8]. Of course, this does not exclude the possibility
that other genetic defects operating through non-renal
mechanisms may be discovered in the future, but it under-
lines the importance of the renal genetic-molecular mech-
anisms of essential hypertension. This importance is also
supported by the overwhelming amount of data, collected
over a period of more than 30 years, that deal with the
crucial interaction between body sodium and renin in
determining the final level of blood pressure and kidney
function. Careful studies of sodium handling by the kidney,
the renin-angiotensin system, the pressor response to so-
dium load or depletion, or to other aspects of renal
function under different experimental conditions may help
to cluster hypertensive patients into discrete subgroups
whose members should should all have the same, more
clearly identifiable renal genetic-molecular mechanisms
[10]. This consideration underlines the crucial role that the
clinical and experimental nephrologist may play in clarify-
ing the pathogenetic mechanisms of essential hypertension.
STRATEGIES FOR IDENTIFYING THE GENETIC
MECHANISMS OF ESSENTIAL HYPERTENSION
How to search and what to search for
When two alleles of two different genes are located in
close proximity on the same chromosome, there is only a
small chance that recombination will occur between them
and thay are said to be in linkage dysequilibrium (or to be
associated). The position of a gene on a chromosome is
called its “locus.” In modern terminology a locus comprises
not only genes but also genetic units without a known
function. The concept of linkage dysequilibrium can also be
applied to phenotypes. When two phenotypes occur to-
gether in the same individual more often than expected by
chance, as for the type A blood group and cancer of the
stomach [11], they are said to be associated or to be in
linkage dysequilibrium. One of several possibilities is tight
linkage of the two genes that determine the two associated
phenotypes. Taken in its broadest sense, the term linkage
dysequilibrium is now currently employed to indicate that a
certain locus is associated with a certain disease [reviewed
in 12]. When used in this way, it indicates that the occur-
rence of a particular genotype for a locus occurs more often
than expected when the disease under investigation is
present. This only signifies that the locus is of interest, that
is, that a gene possibly involved in the pathogenesis of the
disease is located in proximity to the identified locus,
whereas the observed genotype is only a “genetic” marker
of the disease but does not allow any speculation on which
is the gene that determines the disease. A genetic marker is
thus any identifiable DNA segment that may be in linkage
dysequilibrium with the disease of interest. A marker can
be a particular variant or allele of any DNA segment or
gene that is in tight linkage with the disease allele. Cur-
rently the most used DNA markers are anonymous poly-
morphic DNA markers that are widely and homogeneously
distributed across the whole genome. They are derived
from repetitive sequence elements based either on short
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(microsatellite) or longer (minisatellite) domains that are
repeated in tandem. There are numerous possible alleles
for such markers (up to 30 to 40), which are thus highly
polymorphic. Such a large number of alleles has a practical
utility for geneticists, as they provide the possibility of
observing transmission of the marker with that of the
phenotype under investigation.
Two conceptually different approaches may be employed
in the study of genetic determinants of essential hyperten-
sion. The first is the candidate gene approach, which takes
advantage of polymorphism in genes that encode proteins
of known or suspected importance in blood pressure regu-
lation. The cosegregation with blood pressure of a candi-
date gene variant or of an allele of any kind of DNA marker
(allele of any known gene, RFLP, mini- or microsatellite)
mapping within or very close to the candidate gene is
considered good evidence for a pathogenic role of the gene
under investigation, particularly when functional alteration
of the candidate gene function is also demonstrated. The
second approach, random genome scanning, also may use
anonymous polymorphic DNA markers as well as known
variants of known genes, but it tests many markers in the
same population without previous assumptions on which is
or where is the disease gene. An identified genetic locus
influencing a quantitative trait such as blood pressure is
called quantitative trait locus (QTL) [13]. It is important to
remember that when blood pressure QTLs are being
sought by genome scanning, a very large number of loci are
evaluated in the same experimental unit. To avoid numer-
ous false positives, such experiments should set a signifi-
cance level in the range of P , 1025 [14], although there is
no general consensus on such stringent criteria.
At present no agreement exists as to the most suitable
kind of sample to study and genetic strategy to adopt in
order to identify the genes that cause essential hyperten-
sion. Two distinct general strategies are available: linkage
analysis and association analysis. Each one has specific
advantages and drawbacks. Both linkage and association
methodologies are powerful and useful to detect and map
genes potentially responsible for many human disorders.
There are major differences in the particular “material”
used as linkage analyses are applied to families and asso-
ciations to the general population. Although linkage stud-
ies are powerful methods for detecting disease loci, they
depend heavily on the a priori hypothesis that a single major
locus is responsible for susceptibility to the disease and,
moreover, they are sensitive to errors in parameters used in
the genetic model, unless nonparametric approaches are
used. On the other hand, as essential hypertension is a
multifactorial disease, the genetic association strategy has
the advantage of being able to detect not only major gene
effects but also minor ones, which may not be revealed by
linkage analyses. A conspicuous drawback of association
analysis is that it is much more sensitive to increases in
genetic distance of the marker from the disease locus,
making it more suitable to test candidate genes than to
perform a complete genome scan, which would require an
immensely large (and dense) number of markers [15].
Furthermore, particularly in the case of essential hyperten-
sion, precise definition of the control sample is critical. This
is the weakest point of any association study, as the gross
phenotypic definition of “healthy” or “not affected” may
not be precise enough due to the heterogenous polymor-
phic etiology of a complex, multifactorial trait.
Genetic analysis of essential hypertension, as that of any
other complex disease, suffers from three fundamental
complications.
(1) Each gene may have only a small quantitative effect on
the disorder. This implies that the relative risk for the
genotype, that is, the increased chance that an individual
with a particular genotype for a particular allele has the
disease, is small and that a substantial number of nonaf-
fected individuals can be found with the genotype of the
affected ones. Risch and Merikangas recently considered
this problem in detail and concluded that linkage analysis
has only a limited power to detect genes of modest effect
such as those that are implicated in the pathogenesis of
essential hypertension. Their argument is that, for alleles
occurring with a relatively high frequency in the population
and yet confer a relatively small genotype risk, linkage
analysis provides few chances to identify disease loci be-
cause the number of families required, several hundreds to
thousands, is currently far beyond anyone’s ability [16].
(2) It is likely that essential hypertension is genetically
heterogeneous. However, all linkage methods focus on a
single locus at one time in the expectation (hope) that if
that locus “accounts for a high enough proportion of cases
it can be detected” [17]. Statistical tests for heterogeneity
should thus be used before rejecting the hypothesis of
linkage for a candidate gene.
(3) Epistasis is very likely to be present in essential hyper-
tension. Frankel and Schork have recently discussed two
examples of epistatic interaction in determining cancer
susceptibility in mice [18]. In both cases, there was evidence
for a two-locus system in which neither locus had an effect
per se, and neither would be detectable with standard
linkage designs [19, 20].
Monogenic forms of human hypertension
Monogenic forms of human hypertension are very rare
syndromes in which mutations in single genes are sufficient
to produce large blood pressure changes. Although this
review is concerned with essential hypertension, a brief
description of monogenic forms of hypertension is in-
cluded, as knowledge of these forms may provide new
insights into blood pressure regulation. A recent review on
this topic is in [8].
Liddle’s syndrome. Liddle’s syndrome is an autosomal
dominant form of salt-sensitive hypertension characterized
by early onset, hypokalemia, and low renin and aldosterone
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levels. It can be treated by salt restriction and amiloride
(the selective inhibitor of the epithelial Na channel). A
linkage study in Liddle’s original pedigree demonstrated
linkage to a segment of chromosome 16 containing two
genes, the b and g subunits of the epithelial Na channel,
which were considered plausible candidates because so-
dium reabsorption through this channel is one of the major
determinants of tubular sodium reabsorption [21]. Differ-
ent mutations causing truncation of the cytoplasmic C-
terminus of the b or g subunit have subsequently been
described as responsible for Liddle’s syndrome in different
pedigrees [22–24]. In all cases, premature truncation of the
cytoplasmic C-terminus of either the b or g subunit results
in constitutive activation of the channel (that is, loss of
normal negative regulation of the channel, and hence
increased net renal sodium reabsorption). The critical role
of the epithelial Na channel in maintaining salt and extra-
cellular fluid balance and controlling blood pressure is
confirmed by the finding of different mutations in both the
a or b subunits, either of which cause pseudohypoaldoste-
ronism type I, a rare autosomal recessive disease charac-
terized by neonatal salt wasting, low blood pressure, hyper-
kalemia and metabolic acidosis. Sodium is lost as the
mutations cause a striking decrease in the opening time of
the Na channel (and hence of the sodium reabsorbed) [25].
Pseudohypoaldosteronism type II or Gordon’s syndrome.
This is another rare form of dominant familial hypertension
with low renin, high serum K, normal glomerular filtration
rate and good response to salt restriction and/or thiazide
diuretic treatment. Linkage analysis demonstrated locus
heterogeneity, with in some families significant linkage to
chromosome 17q21 [26], which is syntenic with a segment
of rat chromosome 10 that contains at least one or two
blood pressure QTLs (see below).
Apparent mineralocorticoid excess. Apparant mineralo-
corticoid excess (AME) is an autosomal recessive form of
hypertension, phenotypically similar to Liddle’s syndrome
(low renin and low aldosterone levels) but responsive to
mineralocorticoid (type 1) receptor inhibition by spirono-
lactone. Different mutations in the gene of the 11b-
hydroxysteroid dehydrogenase kidney isozyme cause differ-
ent degrees of loss of function of the enzyme. The kidney
isozyme of 11b-hydroxysteroid dehydrogenase is expressed
in distal and cortical collecting tubules, where the miner-
alocorticoid receptor is also present. It converts cortisol to
cortisone, which has no mineralocorticoid activity, at the
pre-receptor level. When the enzymatic activity is defective,
normal circulating cortisol can thus produce a large miner-
alocorticoid effect by direct stimulation of the mineralocor-
ticoid receptor [27, 28]. Due to the enzyme defect, affected
patients have an elevated urinary tetrahydrocortisol 1
allo-tetrahydrocortisol to tetrahydrocortisone ratio. Re-
cently, a heterozygous hypertensive father of an affected
homozygous proband has been described in a Brazilian
kindred [29]. The interest of this case is that the father, who
also has an altered urinary steroid ratio, had previously
been defined as having essential hypertension, although
with low renin and aldosterone levels and a suboptimal
response to conventional antihypertensive treatment (di-
uretics 1 b-blockers). As the urinary steroid ratio has also
been reported as abnormal in some essential hypertensive
individuals [30], it is possible that subtle defects in 11b-
hydroxysteroid dehydrogenase activity also play a role in
essential hypertension.
Glucocorticoid remediable aldosteronism. Glucocorticoid
remediable aldosteronism (GRA) is an autosomal domi-
nant form of hypertension with low renin but high aldoste-
rone levels, whose secretion is controlled by ACTH and not
by angiotensin II. The disease is caused by unequal cross-
ing-over of chromosome 8 between the aldosterone syn-
thase and 11b-hydroxylase genes, which are tightly linked.
The crossing-over produces a novel chimeric gene, which
contains the proximal (regulatory) sequence of 11b-hydrox-
ylase and the distal (coding) sequence of aldosterone
synthase. In this way the chimeric gene is under the control
of ACTH but its gene product has aldosterone synthase
activity [31, 32].
The rat as a reductionist model for human hypertension
For a long time research on the pathogenetic mecha-
nisms of hypertension focused only on the search for
biochemical/physiological differences between hyperten-
sive and normotensive humans or between spontaneously
hypertensive rats and their respective normotensive control
strains. Many differences were found and many biochemi-
cal/physiological mechanisms for hypertension have been
proposed. Probably much of that work did not yield mean-
ingful conclusions because, in the case of humans, the
population of hypertensives is too heterogeneous and, in
the case of rats, many of the observed differences between
hypertensive and control strains were simply due to chance
selection and fixation of specific biochemical/physiological
traits rather than real causal differences relevant to the
pathogenesis of hypertension. Modern genetic strategies
are thus based on the search for QTLs, that is, not for the
disease gene itself but for an indication of its approximate
location. Unfortunately, the relative proximity of a QTL to
the disease gene may mean up to 50 to 100 genes.
Rapp has proposed a series of fixed rules (a paradigm) to
test whether a given trait may be important in explaining a
blood pressure difference between cases and controls: (1)
the trait must be different in hypertensives and normoten-
sives; (2) it must follow the Mendelian inheritance pattern;
(3) the genes that affect the trait must cosegregate with
significant blood pressure differences; and (4) it must be
possible to show some logical biochemical or physiological
link between the identified trait and blood pressure [33, 34].
A fifth corollary rule could be the confirmation that the
same kind of association between the trait (or gene mal-
function that causes the specific trait or linkage with a
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corresponding syntenic DNA segment) and hypertension is
present in some rat genetic models and in humans. As the
human and rat diverged about 80 million years ago [35],
there is little chance that the trait that cosegregates with
hypertension is caused by the same mutation in the same
gene. The alternative possibility of a different mutation in
the same gene or a mutation in another gene whose
function is also needed to determine the trait must be
considered as well.
Genetically hypertensive rat strains should provide a
simplified experimental approach as the mechanisms re-
sponsible for hypertension seem different in each rat strain.
All hypertensive rat strains were selected from different
standard laboratory stock colonies by mating the offspring
of a couple according to their blood pressure values
(mating of offspring with higher blood pressure values
originated the hypertensive strain and mating of offspring
with lower blood pressure values originated the normoten-
sive “control” strain) until the character was fixed, that is,
when the hypertensive and control strain reached different
stable blood pressure values. This occurs after at least 21
generations of brother-sister mating. Such an approach has
a major limitation: only blood pressure is measured during
the selection, and the overall genetic background that is
also fixed in the strain during the selection contributes to
the final blood pressure. To complicate the picture, it may
happen that alleles tending to increase blood pressure in
the normotensive strain and/or alleles tending to decrease
blood pressure in the hypertensive one also may eventually
be fixed. Moreover, during the process of fixation, other
genetic differences unrelated to hypertension may be fixed
as well. Due to such random fixation of different genotypes
for alleles unrelated to blood pressure control, the finding
of a genetic difference between the affected and the
unaffected strain can by no means be taken as evidence that
such a genetic difference is related to hypertension. One
way to overcome the problem of chance fixation is by
studying segregating populations. In this kind of experi-
mental approach the hypertensive and control strain are
crossed in order to ascertain if a particular genotype or
intermediate phenotype segregates with higher or lower
blood pressure levels.
One hypertensive parent and one normotensive mate to
produce a first generation (F1) of hybrid offspring, which
then mate to produce F2 offspring (F1 x F1). By definition,
all F1 animals will be heterozygous for all the genes which
are different in the parental strains, and a complete mix-up
of the genes will be obtained in the F2. It is then possible to
test whether the F2 animals with higher blood pressure
values differ from those with lower blood pressure values in
any specific biochemical/physiological trait, candidate locus
or particular allele. The demonstration of a relationship
between a given locus and blood pressure indicates that one
gene present in the DNA segment around the locus is a
potential candidate for blood pressure control. As this
segment may contain a large number of genes, additional
genetic, physiological and/or biochemical studies are
needed to establish which gene is the one most likely to be
responsible. A major drawback of experiments performed
in F2 segregating populations lies in the uniqueness of the
individual animals, so that it is practically impossible to
extensively characterize the animals for the intermediate
phenotypes of interest.
Recombinant inbred and congenic strains provide a
powerful alternative to segregating F2 populations for
localizing and identifying candidate genes. They are per-
manent strains which can then be extensively characterized
also for all intermediate phenotypes in different genetic
backgrounds [36, 13]. Recombinant inbred strains are pro-
duced by random mating of pairs of F2 animals, followed by
mating of the offspring of each couple for at least 20
generations to fix the characters again. Genetic analysis is
then performed by testing if hypertension is inherited with
the genotype of the affected original strain. Once a chro-
mosomal region associated with hypertension in an F2 or
recombinant strain has been found, congenic strains are
produced by back-crossing an F1 possessing the chromo-
somal region of interest from the hypertensive strain with
the control strain (obviously the reverse possibility of
transferring the “normotensive” segment of DNA into a
hypertensive genome is possible as well). This procedure is
performed for several generations, and the length of the
transferred DNA segment is checked with appropriate
DNA markers mapping at known distances until the con-
genic animals are identical to the parental strain with which
they are back-crossed, except for the DNA segment of
interest. Many variants of this technique are available. It is
possible simultaneously to select for more than one DNA
segment as well against one or more other DNA segments
with appropriate genotyping before mating. This technique
achieves a real DNA transfer (transplant) from a hyperten-
sive strain in a normotensive genome and may provide
definitive evidence that the transferred DNA segment
contains at least one gene that affects blood pressure. If the
phenotype of the congenic strain differs from that of the
recipient progenitor strain, this proves the existence of a
locus affecting that phenotype in the transferred chromo-
somal segment.
Many QTLs have been found in the different genetic
hypertensive rat strains. As some happen to be on the same
chromosome they are presented by chromosome rather
than by candidate gene in Table 1.
Genetic manipulation provides a powerful tool for
biochemical physiological studies
Modern molecular biology techniques can be used to
create strains of transgenic animals, which are a powerful
experimental tool to test specific hypotheses on candidate
genes of essential hypertension. In a transgenic animal a
foreign DNA segment (not necessarily of the same species)
is introduced artificially in such a way that it is incorporated
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Table 1. Summary of the most important findings of chromosomal loci found associated with hypertension in different rat strains
Chromosome Locus Comments Strains/crosses
1 SA SA gene: protein of unknown function [37], expressed 10 times more in SHR than in WKY
proximal tubuli [38–40]. Associated with blood pressure in several F2 crosses [41, 42]. SA gene




P450 Suggested presence of another QTL after Na loading, 55 cM from the SA locus, around a cluster
of cytochromes P450 loci [45].
SS/Jr 3 Lew
b & g Na
channel




Kallikrein Kallikrein maps on chromosome 1 and was found linked to hypertension [48]. SHR 3 BN
D1Mit3/Igf2 Chromosomal region associated with a locus that reduces blood pressure, observed in a congenic
SHR strain receiving the chromosomal segment from BN [49].
2 ANF receptor Atrial natriuretic peptide receptor A (GCA) gene more expressed in glomeruli of SHR than SD,
Wistar and WKY [50]. Linkage of GCA locus confirmed in different crosses [51, 52] and two con-







A clear causal role of the GCA gene cannot be demonstrated since this region is densely
populated of other possible canidate genes (a1 subunit of the Na1,K1-ATPas [54, 55], 3b-
hydroxysteroid dehydrogenase, angiotensin II receptor AT1B [56]).
3 ET3 One positive [57] and one negative [58] linkage study for endothelin 3. SS/Jr 3 SR/Jr
SS/Jr 3 Lew
4 R514 QTL not yet associated with a candidate gene [59]. SHR 3 BN
NPY QTL associated with the neuropeptide Y gene [60]. SHR 3 WKY
a Na channel No linkage for a subunit of the epithelial Na channel [46]. SHR-SP 3 WKY
5 ET2
P4504A
Linkage with endothelin 2 locus [58]. Reduced cytochrome P4504A gene expression (3.3 cM
distant from ET2 gene) in renal medulla of SS/Jr as compared to Lew rats [61].
SS/Jr 3 Lew
7 11b-HD The Salt resistance of SR/Jr rats may be partly due to reduced 18OH-DOC synthesis caused by
mutation(s) in the 11b-hydroxylase gene [62]. The protein of SR/Jr rats contains five amino
acidic substitutions. Two of them correlate with a functional alteration of the enzyme and are






Significant QTL, explaining about one eighth of the genetic variance of blood pressure [49] is
associated with brain dopamine receptor and renal epithelial potassium channel. Data
confirmed with congenic SHR receiving the chromosomal segment from BN [64].
SHR 3 BN
10 ACE/GH Strong association between blood pressure and some markers on a region near the ACE gene in
several crosses [52, 65–67]. Although five mutations were found in SHR-SP ACE coding
regions, only one changes the amino acid, but the gene product has normal Km and Vmax [68].
However, the ACE locus seems associated only with ACE activity, not blood pressure





A QTL associated with basal blood pressure is located 26 cM from the ACE locus (SP-BP1a)
whereas another (SP-BP1b) QTL associated with blood pressure after Na load is much closer
to the ACE locus (congenic and recombinant strains from SHR and WKY) [70].
Nos2 Alleles of the inducible nitric oxide synthase gene cosegregate with blood pressure. Nos2 maps
27–32 cM from the ACE locus [71].
SS/Jr 3 MNS
SS/Jr 3 WKY
13 Renin Cosegregation with blood pressure in different F2 populations [72–76]. No linkage to kidney renin
concentration [77] and no point mutation in the renin gene coding region were found [78]. The
chromosomal segment carrying the “hypertensive” renin allele is associated with low renin and low
blood pressure [79]; the opposite was found in rats carrying the “normotensive” renin allele
(congenic Dahl rats) [80]. Conclusion: the hypertensive effect of the “hypertensive” renin allele, if








A segment of 91.6 cM on chromosome 13 (comprising the renin locus) demonstrated a broad
peak of linkage to hypertension. The major peak is 21.7 cM from the renin gene. In this
chromosomal region there are at least two other known candidate genes for hypertension or
its complications: the cardiac isoform of troponin T (less than 3 cM from the renin gene) and
the a2 subunit of the Na1,K1-ATPase gene less than 60 cM away), although the latter did not
reach statistical significance for linkage [55].
SHR 3 WKY
14 a-Adducin Missense mutations found in the coding region of a-adducin and b-adducin (which maps on chromo-
some 4). Their epistatic interaction explains up to 50% of the blood pressure difference between
MNS and MHS rats [81]. The “hypertensive” a-adducin variant affects actin assembly, and stimu-
lates the Na1,K1-ATPase activity in a cell free system and in transfected renal tubular cells [82, 83].
MHS 3 MNS
17 MITH Testis-specific histone locus cosegregates significantly with high blood pressure [58]. SS/Jr 3 Lew
19 AGT The angiotensinogen locus does not seem involved in blood pressure control in rats [84, 85]
although tissue-specific angiotensinogen gene expression is different in SHR and WKY [86].
SHR-SP 3 WKY
20 HSP Heat-shock protein 70 (HSP70) and heat shock protein 27 (HSP27) genes are overexpressed in
response to various stresses in rats and are genetically linked to hypertension [87, 88].
SHR 3 WKY
SR 3 BN
Y Tty Linkage to the Y chromosome in SHR and SHR-SP [89–91], not confirmed in a different SHR stock
[92]. The proposed candidate gene is Tty, which affects the timing of testosterone secretion [93].
SHR 3 WKY
SHR-SP 3 WKY
X Sp-BP3 A QTL was found in an F2 population [65]. SHR-SP 3 WKY
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into the germline. This is usually achieved by microinjec-
tion of the foreign DNA into the male pronucleus of a
fertilized oocyte. The injected DNA integrates randomly
into the recipient’s chromosomal DNA. As the result of
chromosomal integration, the transgenes are passed in
Mendelian fashion to subsequent generations. Random
integration has the substantial drawback that the transgene
is present together with the original genes, and its expres-
sion may be influenced by promoters of other genes where
the integration occurred. Gene expression can be tested in
specific target tissues by transplantation of tissue specific
promoters. A more elegant as well as more technically
difficult alternative is that of gene targeting by homologous
recombination, that is, physical replacement of a natural
gene with a cloned one by homologous recombination. The
advantage of this technique is that replacement occurs in
the natural gene’s original DNA location. The disadvantage
is that, so far, this technique is applicable only to one
particular strain of mice. The cloned gene may be a
nonfunctional one and cause inactivation of gene expres-
sion (knock-out mutation). It may carry a putative patho-
genic mutation or alternatively may restore the healthy
allele, so that one may test the hypothesis that a specific
candidate gene causes the disease.
Transgenic rats created by microinjection of the mouse
renin-2 gene into non-hypertensive non-inbred Sprague-
Dawley rats have fulminant hypertension, low plasma re-
nin, enhanced corticosteroids secretion and several other
developmental and regulatory abnormalities [97]. Mice
carrying from 0 to 4 functional copies of the murine
wild-type angiotensinogen (AGT) gene at its normal chro-
mosomal location have a significant and almost linear
increase in blood pressure and serum AGT concentration
per gene copy, although the normal compensatory mecha-
nisms are intact [95]. Substantially similar results were
obtained in transgenic mice receiving the rat AGT gene
[96]. Transgenic mice carrying both the human renin and
the human AGT genes under the control of their native
promoters have high blood pressure and may be a good
model for human high renin hypertension [97]. Disruption
of the angiotensin converting enzyme (ACE) gene in mice
reduced blood pressure by about 50% and serum ACE
activity to zero [98], whereas when only one functional
allele was left blood pressure remained normal, ACE
activity was reduced by about 50% and renal renin mRNA
increased fourfold [99]. Three functional copies of the
ACE gene left blood pressure normal despite a 50%
increase of serum ACE activity. These studies indicate that
important homeostatic adaptations normalize the blood
pressure of mice in spite of changes in ACE gene function,
and that only large changes of ACE gene expression affect
blood pressure, exceeding the capacity of the homeostatic
mechanisms [100].
Transgenic mice expressing the human tissue kallikrein
gene have lower blood pressure than controls [101]. Mice
homozygous for atrial natriuretic peptyde (ANF) gene
inactivation had hypertension on a normal salt diet whereas
heterozygous ones had hypertension only with a high salt
diet, demonstrating that genetically reduced production of
ANF can lead to salt-sensitive hypertension [102]. The
opposite experiment consisted of the production of trans-
genic mice with a fusion gene composed of mouse trans-
thyretin (TTR) promoter fused to the mouse ANF struc-
tural gene. This gene is continuously expressed in the liver
and its end effect is a chronic elevation of plasma ANF
concentration. The mean arterial blood pressure of trans-
genic animals harboring the TTR-ANF fusion gene was low
and inversely proportional to hepatic ANF expression
[103].
Transgenic mice overexpressing the Na-H exchanger
reabsorb more sodium and water and increase their systolic
blood pressure after salt loading [104]. Targeting disruption
of the angiotensin II type 1A receptor gene reduced the
blood pressure by 12 mm Hg in heterozygous mice and by
25 mm Hg in homozygous mice [105]. Disruption of the
endothelin 1 (ET1) gene caused death at the birth of
homozygotes, whereas heterozygotes (which produced
lower levels of ET1 than wild-type mice) became hyperten-
sive [106]. Also, endothelial nitric oxide synthase (eNOS)
gene disruption caused hypertension [107].
Genetic analysis in human hypertension
The mass of available data on experimental animals is
overwhelming. Almost all rat chromosomes contain at least
one QTL, so interpretation of this “genetic soup” is partic-
ularly difficult. There are far fewer positive results in
humans, and we propose to analyze the data on the
renin-angiotensin system and adducin in detail, as in each
case both linkage and association studies were positive and
confirmed in different populations. Negative or uncon-
firmed results for other candidate loci are summarized in
Table 2.
Renin-angiotensin system.
(a) Renin locus. No significant difference was found in
the distribution of the alleles between hypertensives and
normotensives, nor was an excess of alleles detected in
affected sib-pairs [134–136], although a Japanese case-
control report found an association with a family history of
hypertension [137]. Although these data are not sufficient
to definitively exclude the renin locus, they are a strong
indication against its involvement in the pathogenesis of
human essential hypertension.
(b) Angiotensinogen. Variants of the AGT gene have
been studied extensively in humans since the first demon-
stration [138] of their involvement in human essential
hypertension. AGT is the substrate of renin and its plasma
level or amino acidic sequence may affect angiotensin I
production by a given level of renin. Ten diallelic polymor-
phisms have been identified in the AGT gene [139]. The
M235T polymorphism affects plasma AGT levels, which
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are lowest in hypertensive individuals homozygous for the
M235 variant, intermediate in heterozygous ones and high-
est in homozygotes for the 235T variant. The latter allele is
more frequent in hypertensives than in normotensives. It
appears that a mutation in the promoter, 6 bp upstream
from the initiation site of transcription, in tight linkage with
the M235T variant, is the causal mutation [140] as it affects
the basal transcription rate. It is associated with early onset
of hypertension [141, 142]. The association between 235T
and hypertension has been confirmed in several popula-
tions [143, 144] in spite of large differences in allele
frequencies [145, 146]. In some Caucasian samples the
association was not confirmed but the number of subjects
was probably too small [147–149]. Significant linkage was
confirmed in a group of English families [149] and among
Afro Caribbeans [150]. The renovascular response to an-
giotensin II infusion was blunted in hypertensives with the
235T genotype, and this is relevant to the development of
hypertension as an intrinsic activation of the kidney renin-
angiotensin system may be present in these patients [151].
(c) Angiotensin converting enzyme. A 287 base pair inser-
tion (I)/deletion (D) polymorphism in intron 16 of the gene
encoding ACE has been shown to affect its plasma levels
[152, 153] and the blood pressure response to infused
angiotensin I [154]. This extensively tested polymorphism
does not seem directly involved in essential hypertension
[155–158]. The age-related increase in the I allele fre-
quency (associated with low serum ACE) in hypertensives
[159, 160] was interpreted as excess mortality in elderly
hypertensives carrying the D allele. The D allele is variably
associated with complications of hypertension as myocar-
dial infarction or ischemia [161, 162], ventricular hypertro-
phy [163, 164] and carotid artery thickness [165], although
two large studies challenged the association of the D allele
with ischemic heart disease and myocardial infarction [166,
167]. The negative ACE locus findings conflict somewhat
with the positive ones in rats. Very recently a linkage study
on a large number of affected sib pairs (518 sib pairs)
provided strong evidence of linkage for a marker 18 cM
centromeric with respect to the ACE locus on chromosome
17 [168]. This study is important for two reasons: (1) It used
a different strategy to locate a susceptibility locus for
human essential hypertension. Instead of looking for a
pathophysiologically plausible candidate gene, the authors
tested a region of a human chromosome that is syntenic to
a rat one, already found linked to rat hypertension. (2) The
peak of significance found is practically superimposable on
the one reported in some families with Gordon’s syndrome
(Fig. 1) [26]. Gordon’s syndrome is treatable with thiazide
diuretics. The resemblance to essential hypertension needs
further studies.
Adducin. The possible involvement of the a-adducin
locus on chromosome 4p16.3 in blood pressure control was
tested by polymorphic markers mapping at various dis-
tances from the locus in a case-control study [169] and in a
sib-pair study [170]. Positive results were obtained in both
studies. Variants in the a-adducin amino acidic sequence
were also detected, one of which (Gly460Trp) was associ-
ated with essential hypertension [170]. The blood pressure
of heterozygous hypertensive patients was more sensitive to
changes in sodium balance and the administration of
diuretics compared to that of patients homozygous for the
more frequent Gly460 variant [170], and the slope of the
pressure natriuresis function was less steep as in cases of
hypertension caused by a primary increase in tubular
sodium reabsorption [171]. Sodium handling in the rare
Try460Try homozygotes seems similar to that in het-
erozygotes. The association has been confirmed in two
case-control studies, one of a Caucasian and one of a
Japanese ethnic origin [172, 173].
Table 2. Candidate loci studied in humans, which are negative or not yet confirmed by other studies for linkage and association with hypertension
Locus Comments Reference
SA gene One positive case-control study on a Japanese sample has not been confirmed and is not associated with
renal function abnormalities
[108–110]
Angiotensin receptors One positive and one negative case-control study; one negative linkage study. No interaction with AGT
gene variants.
[111, 112]
Insulin receptor Positive case-control studies, mainly on hyperinsulinemic hypertension, but negative linkage study,
possibly due to small sample size.
[113–116]
Glucagon receptor One positive and one negative case-control study. [117, 118]
ANF One positive association study on a small sample of Afro-Americans; two negative studies. [119–121]
Endothelin and endothelin
receptor
One negative study in which a relation was found between blood pressure and genotypes in the
normotensive control group only.
[122]
Na-H exchanger One negative linkage study in pedigrees with major gene segregation of elevated Na-Li
countertransport.
[123]
Nitric oxide synthase No evidence of linkage or association in several studies. [124–126]
Kallikrein Two negative case-control studies. [127]
Blood groups and HLA Scanty reports of positive linkage and/or association with HLA locus and MN blood groups indicate that
some QTLs for blood pressure are present on human chromosomes 4 and 6.
[128–103]
Lipoprotein-lipase Two positive linkage studies in a subset of Taiwanese families at high risk for insulin resistance and
non-insulin dependent diabetes mellitus.
[131]
1p36 Undefined marker locus on chromosome lp36. [132]
b2-Adrenoceptor Unconfirmed linkage study in African Caribbeans. [133]
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In conclusion, AGT and adducin seem to be the only
genes for which at least two association studies and one
linkage study yielded positive results in human essential
hypertension. However, there are fewer published studies
from independent groups of investigators on adducin than
on AGT.
Comparison between animal and human results. Only
three genes (or loci) have been found positive in humans in
different populations compared with the numerous positive
results in animals. There are two possible explanations for
the discrepancy: (1) The number of genes involved in
human essential hypertension is greater than the number
responsible for hypertension in individual rat strains. This
produces a “dilution” of the effect of a given gene when an
unselected population of hypertensive patients is tested for
either association and/or linkage. (2) The experimental
set-up may influence the results. Studies in rats were
performed after more than 20 generations of brother-sister
mating (followed, if necessary, by several specific back-
crosses). The situation is obviously greatly different in
humans, where random mating occurs. Furthermore, the
conditions of blood pressure recording in rats have been far
from physiological in most of the published experiments
(pre-warming and handling of the animal for indirect
tail-cuff measurements or insertion of a catheter in a
carotid artery and only few hours of recovery after anes-
thesia). Certainly the genes (or loci) detected in rats all
code for (or are linked to genes that code for) proteins
whose function is somehow involved in blood pressure
regulation. At present it is unknown to what extent the
artifacts induced by such stressful protocols amplified the
role played by genes that might have provided only a minor
contribution to blood pressure control if the animal had
been studied in its own natural environment and allowed to
mate randomly.
In this light, positive, ambiguous and negative results
obtained in humans are all relative terms. As previously
noted, it seems likely that the genotype relative risk for
human essential hypertension genes detected thus far is
very low (for the M235T variant of AGT from different
studies, we calculated that for Caucasians it is about 1.5 to
1.6; that of adducin is 1.8 [170]). According to the calcula-
tions of Risch and Merikangas, significance for a sib pair
study could be expected only for a much larger sample size
than that used in the positive linkage studies published (at
least 500 to 600 sib pairs for AGT and 250 to 350 for
adducin) [16]. Furthermore, individual research units will
rarely be able to collect sufficiently large sample sizes that
can reach enough power to yield statistically convincing
results. In this regard large collaborative studies such as the
recent European study on AGT [174] may be of little use,
because marker allele frequencies are likely to vary be-
tween different populations. In spite of this difficulty, more
stringent criteria are being proposed for declaring positive
linkage, as multiple testing may indeed increase the chance
of finding false positive results [14]. Though not all authors
agree [175], the problem of false positive results, together
with the symmetric one of too weak and hence rejected true
positive findings, remains. In a comment specifically about
mental illness, which is equally applicable to essential
hypertension, Risch wrote that false-negative results may
be more damaging to the field than false-positive ones
[176]. Is it possible to avoid the risk of false positives by
using alternative approaches to investigate the pathoge-
netic mechanisms of essential hypertension?
Fig. 1. Linkage map of a region of human chromosome 17 synthenic to
that of rat chromosome 10, where SP-BP1a and SP-BP1b have been
detected. (A) Redrawn and simplified from a sib-pair study in 518 pairs of
hypertensive sibs [168]. (B) Redrawn from two pedigrees with Gordon’s
syndrome [26]. The letters on the x axis refer to the genes identified in the
region.
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THE FUTURE DIRECTION IS BACK TO
PHYSIOLOGY
A reasonable alternative possibility is focusing on linkage
(and on linkage dysequilibrium) of very precisely defined
candidate genes. They should be tested based on rational
hypotheses and solid experimental data showing their
pathogenetic importance in causing intermediate pheno-
types (for example, salt-sensitivity, pressor response to
stress, pressor response to angiotensin, etc.). Linkage of the
candidate gene and their epistatic interactions should be
sought with both the intermediate phenotype and blood
pressure. The solid pathophysiological background of
knowledge, supporting the role of the kidney in the control
of blood pressure via the modulation of body sodium, fluids
and renin, may be used to unravel the genetic causes of
human essential hypertension. Certainly other mechanisms
are important in blood pressure control. However, in our
opinion (or perhaps bias), the mechanisms related to
sodium balance and renin rank first in the hierarchical
organization of the long-term control of blood pressure.
Many experimental demonstrations suggest that the causes
of stable hypertension must in some way affect the pres-
sure-natriuresis relationship. For example, a chronic sub-
pressor infusion of angiotensin changes the pressure-natri-
uresis function in the dog and makes it salt-sensitive [177].
Most of the positive linkage studies in rats and humans
indicate some abnormality in the renin-angiotensin system
in the direction of increased activity of any of its compo-
nents (renin, ACE, AGT) [178], together with some alter-
ation in renal sodium handling. This impressive body of
both pathophysiological and genetic data should stimulate
efforts to understand the interactions among the genes that
control the renin-angiotensin system and renal sodium
handling either directly at the tubular level or indirectly
through hormones that affect tubular sodium reabsorption.
In fact, the most important challenge in the genetics of
essential hypertension is how to assess the role of a given
gene in humans over the large polygenic and environmental
background noise. Certainly all the sophisticated genetic
analyses proposed by the statisticians are very helpful.
However, we doubt that they will give us the final answer;
after all, statistics is only a methodological tool.
Alternatively, we may organize the available knowledge
of a complex physiological system like the control of blood
pressure in a hierarchical fashion from the most important
to the least important mechanism, and the mechanism that
must always be involved in the control of the set point of
blood pressure regulation should rank first. For instance,
comparison of the data on the role of the renal pressure-
natriuresis function and its relation with renin in long-term
control of blood pressure with the data on the role of the
sympathetic nervous system shows that the former ranks
before the latter, in our opinion. Therefore, polymorphism
of the genes that control the first mechanisms should always
be assessed in any population study. Studies of the role of
polymorphism of other genes controlling other mechanisms
may be integrated. It is crucial to know the number of
subjects needed to ensure the proper power to the study.
According to Risch and Merikangas’ above-mentioned
calculation the number of sib pairs needed to assess the
effect of minor genes in linkage studies, we should estimate
the optimum size of a given population sample to ensure
enough power for the study of a given number of genes with
their epistatic interactions. The large sample size required
may be prohibitive, and therefore efforts should be made
on the one hand to select the most pathophysiologically
meaningful gene polymorphism, and on the other to set up
the appropriate statistical tools or new computational
approaches [18].
Following this line of thought, as an example of our
experimental and possibly theoretically biased approach to
these problems, we briefly summarize our study of adducin
as a paradigm.
ADDUCIN AS PARADIGM FOR THE SEARCH FOR
GENETIC MECHANISMS OF ESSENTIAL
HYPERTENSION
Adducin was identified as a candidate gene after a long
series of comparisons between MHS and MNS rats at
different levels of biological organization [reviewed in 179].
Such studies demonstrated that the development of hyper-
tension in MHS is accompanied by renal sodium retention,
normalization of a higher glomerular filtration rate and a
relative increase of a lower plasma renin activity (compared
to MNS of the same age). These experimental results,
together with the possibility of “transplanting” hyperten-
sion with a kidney transplant, led to the hypothesis that
hypertension in MHS was caused by a genetically deter-
mined increase of renal tubular reabsorption of sodium.
The higher glomerular filtration rate was also confirmed in
MHS isolated kidney preparations in which increased
tubular sodium reabsorption was also observed. Sodium
transport was also faster in isolated tubuli and in isolated
luminal and basolateral membranes from MHS. As a
similar increase of sodium transport rate was also detected
on the erythrocyte membrane, the latter were used to
identify the underlying molecular mechanism. In erythro-
cytes the faster sodium transport was genetically deter-
mined and genetically associated with higher blood pres-
sure values in segregating the F2 (MHS x MNS)
populations. As the faster erythrocyte transmembrane so-
dium transport could be normalized by removal of the
membrane skeleton proteins, we hypothesized that one of
the membrane skeleton proteins could play a role in the
faster sodium transport rate of the MHS. Then, with
cross-immunization of membrane cytoskeleton proteins, we
found that adducin was different in MHS and MNS.
Sequencing MHS and MNS a and b subunits of adducin
led to the identification of the already mentioned variants
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that interact epistatically in determining the blood pressure
difference between MHS and MNS [81]. Complementary
DNA transfection of MHS or MNS adducin as well as
incubation of the MHS or MNS adducin variant with
purified Na1,K1-ATPase (the enzyme that produces the
driving force for tubular sodium reabsorption) demon-
strated that MHS a adducin stimulates the Na pump at a
much lower concentration than MNS a adducin [82, 83].
Also, in humans case control studies in three indepen-
dent cohorts [170, 172, 173] and one linkage study [170]
confirmed the involvement of adducin polymorphism in
essential hypertension. In particular, hypertensive patients
carrying the hypertensive variant were more sensitive to
changes in body sodium than patients carrying the wild-type
variant. This finding strongly supports the notion that the
“hypertensive” a adducin allele has a role in the control of
tubular reabsorption of sodium and blood pressure in both
MHS rats and hypertensive humans. The very high amino
acid homology (;94%) between human and rat adducin
suggests that the same biological role is played in the two
species, and that even small changes in the amino acid
sequence can affect its biological function. However, the
mutation is not the same in rats and humans, and so far
only the rat variants have been transfected in tubular cells
and studied in a cell-free system with isolated renal
Na1,K1-ATPase. The same studies also should be carried
out on the human variant to assess the similarities between
humans and rats at the molecular level.
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